| Dynamics of clinical biomarkers as predictors of immunotherapy benefit in metastatic melanoma patients A Hernando-Calvo, A Garcia-Alvarez, G Villacampa, C Ortiz, D Bodet, ... Clinical and Translational Oncology 23, 311-317, 2021 | 13 | 2021 |
| Novel classes of immunotherapy for breast cancer A Hernando-Calvo, DW Cescon, PL Bedard Breast Cancer Research and Treatment, 1-15, 2022 | 9 | 2022 |
| Impact of pharmacodynamic biomarkers in immuno-oncology phase 1 clinical trials A Salawu, A Hernando-Calvo, RY Chen, DV Araujo, M Oliva, ZA Liu, ... European Journal of Cancer 173, 167-177, 2022 | 3 | 2022 |
| First-in-human Phase I study of the bifunctional EGFR/TGFβ fusion protein BCA101 in patients with EGFR-driven advanced solid cancers F Janku, GJ Hanna, RD Carvajal, PK Paik, A Hernando-Calvo, ... Headache 2 (2), 6.1, 2021 | 3 | 2021 |
| Impact of pharmacodynamic biomarkers in immuno-oncology (IO) phase 1 clinical trials. A Salawu, R Chen, A Hernando-Calvo, DV Araujo, M Oliva Bernal, Z Liu, ... Journal of Clinical Oncology 39 (15_suppl), 2653-2653, 2021 | 2 | 2021 |
| ItRECIST adapted efficacy assessment in solid tumors treated with intratumoral immunotherapy. HK Oberoi, X Serres-Créixams, G Alonso, I Matos, A Hernando-Calvo, ... Journal of Clinical Oncology 39 (15_suppl), 2557-2557, 2021 | 2 | 2021 |
| Molecular profiling and targeted agents in recurrent, metastatic salivary gland tumor (R/M SGT) patients (pts) treated at two academic centers. A Hernando-Calvo, A Rezqallah, ER Malone, O Saavedra Santa Gadea, ... Journal of Clinical Oncology 39 (15_suppl), 6081-6081, 2021 | 2 | 2021 |
| Dose expansion results of the bifunctional EGFR/TGFβ inhibitor BCA101 with pembrolizumab in patients with recurrent, metastatic head and neck squamous cell carcinoma. GJ Hanna, JM Kaczmar, DP Zandberg, DJL Wong, E Yilmaz, EJ Sherman, ... Journal of Clinical Oncology 41 (16_suppl), 6005-6005, 2023 | 1 | 2023 |
| Response to “Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint … G Villacampa, A Hernando-Calvo, R Berché, O Saavedra, D Marmolejo, ... Cancer Treatment Reviews 111, 2022 | 1 | 2022 |
| Selinexor for the treatment of recurrent or metastatic salivary gland tumors: results from the GEMS-001 clinical trial. A Hernando-Calvo, E Malone, D Day, A Prawira, I Weinreb, H Wong, ... | 1 | 2022 |
| A phase 1 trial of the bifunctional EGFR/TGFβ fusion protein BCA101 alone and in combination with pembrolizumab in patients with advanced solid tumors. PL Bedard, A Hernando-Calvo, RD Carvajal, VK Morris, PK Paik, ... Journal of Clinical Oncology 40 (16_suppl), 2513-2513, 2022 | 1 | 2022 |
| Abstract P154: Genomic profiling and matched therapy for recurrent or metastatic salivary gland neoplasms. Results from the matched cohort of the GEMS-001 clinical trial A Hernando-Calvo, E Malone, D Dai, A Prawira, I Weinreb, A Eliason, ... Molecular Cancer Therapeutics 20 (12_Supplement), P154-P154, 2021 | 1 | 2021 |
| Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials I Matos, G Villacampa, C Hierro, J Martin-Liberal, R Berché, A Pedrola, ... European Journal of Cancer 155, 168-178, 2021 | 1 | 2021 |
| A risk stratification model for toxicities in phase 1 immuno-oncology (P1-IO) trials. A Hernando-Calvo, A Salawu, M Oliva Bernal, DV Araujo, Z Liu, R Chen, ... Journal of Clinical Oncology 39 (15_suppl), 2648-2648, 2021 | 1 | 2021 |
| Evaluating the role of immune-checkpoint inhibitor (ICI) combinations in patients (pts) with unselected “cold” tumors enrolled in early clinical trials (CT). O Saavedra Santa Gadea, A Hernando-Calvo, R Berche, M Vieito, I Brana, ... Journal of Clinical Oncology 39 (15_suppl), 2597-2597, 2021 | 1 | 2021 |
| 572P Limited efficacy of immunotherapy combination regimens in patients with unselected “cold” tumours enrolled in early clinical trials OS Santa Gadea, A Hernando-Calvo, R Berché, I Matos, I Gardeazabal, ... Annals of Oncology 31, S489, 2020 | 1 | 2020 |
| 573P Efficacy of immunotherapy (IT) after prior immune checkpoint inhibitors (ICIs) exposure A Hernando-Calvo, A Valdivia, OS Santa Gadea, I Braña, R Berché, ... Annals of Oncology 31, S489-S490, 2020 | 1 | 2020 |
| 918MO Molecular enrichment and outcomes based on ESCAT levels in metastatic salivary gland tumours (mSGT) patients (pts) treated in early clinical trials A Hernando-Calvo, MAR Aron, ABA Pedrazzoli, M Vieito, ... Annals of Oncology 31, S662-S663, 2020 | 1 | 2020 |
| Clinical biomarkers as predictors of immunotherapy (IT) benefit in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pt) A Hernando-Calvo, O Mirallas, D Marmolejo, E Felip, GV Javierre, ... Annals of Oncology 30, xi25, 2019 | 1 | 2019 |
| Deciphering the tumor microenvironment (TME) dynamics in advanced colorectal (CRC) and pancreatic cancers (PDAC) treated with durvalumab (D) with olaparib (O) or cediranib (C … A Hernando-Calvo, M Han, O Ayodele, BX Wang, M Vila-Casadesús, ... JCO Global Oncology 9 (Supplement_1), 63-63, 2023 | | 2023 |
